NCT06452394 - NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 16, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions

Breast Cancer

Interventions

DRUG

Doxycyclin

Belongs to the class of tetracyclines. It has bacteriostatic activity against a broad range of gram-positive and gram-negative bacteria. Its mechanism of action lies in the binding to the 30S ribosomal subunit

Trial Locations (7)

1272

RECRUITING

Clinique de Genolier, Genolier

5000

RECRUITING

Tumor Zentrum Aarau, Aarau

7000

RECRUITING

Kantonsspital Graubünden, Chur

8401

RECRUITING

Kantonsspital Winterthur, Winterthur

9007

RECRUITING

Kantonsspital St.Gallen, Sankt Gallen

9016

RECRUITING

Tumor- und Brustzentrum Ostschweiz, Sankt Gallen

CH-1011

RECRUITING

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

All Listed Sponsors

lead

Swiss Cancer Institute

OTHER